Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Orthofix Medical (OFIX) EBIT (2016 - 2026)

Orthofix Medical has reported EBIT over the past 17 years, most recently at -$14.4 million for Q1 2026.

  • For the quarter ending Q1 2026, EBIT rose 70.46% year-over-year to -$14.4 million, compared with a TTM value of -$47.0 million through Mar 2026, up 54.88%, and an annual FY2025 reading of -$81.4 million, up 3.77% over the prior year.
  • EBIT came in at -$14.4 million for Q1 2026, down from $494000.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $6.6 million in Q2 2022 to a low of -$59.7 million in Q1 2023.
  • Median EBIT over the past 5 years was -$17.0 million (2025), compared with a mean of -$19.0 million.
  • The sharpest move saw EBIT tumbled 1840.03% in 2023, then skyrocketed 104.3% in 2025.
  • Over 5 years, EBIT stood at -$1.5 million in 2022, then plummeted by 1125.9% to -$18.3 million in 2023, then soared by 37.34% to -$11.5 million in 2024, then skyrocketed by 104.3% to $494000.0 in 2025, then crashed by 3022.27% to -$14.4 million in 2026.
  • Per Business Quant, the three most recent readings for OFIX's EBIT are -$14.4 million (Q1 2026), $494000.0 (Q4 2025), and -$17.0 million (Q3 2025).